畅想未来的重症哮喘决策树

Expert review of respiratory medicine Pub Date : 2024-08-01 Epub Date: 2024-08-20 DOI:10.1080/17476348.2024.2390987
Arnaud Bourdin, Phil Bardin, Pascal Chanez
{"title":"畅想未来的重症哮喘决策树","authors":"Arnaud Bourdin, Phil Bardin, Pascal Chanez","doi":"10.1080/17476348.2024.2390987","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>There are no validated decision-making algorithms concerning severe asthma (SA) management. Future risks are crucial factors and can be derived from SA trajectories.</p><p><strong>Areas covered: </strong>The future severe asthma-decision trees should revisit current knowledge and gaps. A focused literature search has been conducted.</p><p><strong>Expert opinion: </strong>Asthma severity is currently defined <i>a priori</i>, thereby precluding a role for early interventions aiming to prevent outcomes such as exacerbations (systemic corticosteroids exposure) and lung function decline. Asthma 'at-risk' might represent the ultimate paradigm but merits longitudinal studies considering modern interventions. Real exacerbations, severe airway hyperresponsiveness, excessive T2-related biomarkers, noxious environments and patient behaviors, harms of OCS and high-doses inhaled corticosteroids (ICS), and low adherence-to-effectiveness ratios of ICS-containing inhalers are predictors of future risks. New tools such as imaging, genetic, and epigenetic signatures should be used. Logical and numerical artificial intelligence may be used to generate a consistent risk score. A pragmatic definition of response to treatments will allow development of a validated and applicable algorithm. Biologics have the best potential to minimize the risks, but cost remains an issue. We propose a simplified six-step algorithm for decision-making that is ultimately aiming to achieve asthma remission.</p>","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Imagining the severe asthma decision trees of the future.\",\"authors\":\"Arnaud Bourdin, Phil Bardin, Pascal Chanez\",\"doi\":\"10.1080/17476348.2024.2390987\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>There are no validated decision-making algorithms concerning severe asthma (SA) management. Future risks are crucial factors and can be derived from SA trajectories.</p><p><strong>Areas covered: </strong>The future severe asthma-decision trees should revisit current knowledge and gaps. A focused literature search has been conducted.</p><p><strong>Expert opinion: </strong>Asthma severity is currently defined <i>a priori</i>, thereby precluding a role for early interventions aiming to prevent outcomes such as exacerbations (systemic corticosteroids exposure) and lung function decline. Asthma 'at-risk' might represent the ultimate paradigm but merits longitudinal studies considering modern interventions. Real exacerbations, severe airway hyperresponsiveness, excessive T2-related biomarkers, noxious environments and patient behaviors, harms of OCS and high-doses inhaled corticosteroids (ICS), and low adherence-to-effectiveness ratios of ICS-containing inhalers are predictors of future risks. New tools such as imaging, genetic, and epigenetic signatures should be used. Logical and numerical artificial intelligence may be used to generate a consistent risk score. A pragmatic definition of response to treatments will allow development of a validated and applicable algorithm. Biologics have the best potential to minimize the risks, but cost remains an issue. We propose a simplified six-step algorithm for decision-making that is ultimately aiming to achieve asthma remission.</p>\",\"PeriodicalId\":94007,\"journal\":{\"name\":\"Expert review of respiratory medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert review of respiratory medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17476348.2024.2390987\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert review of respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17476348.2024.2390987","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

简介关于重症哮喘(SA)的管理,目前尚无有效的决策算法。未来的风险是关键因素,可以从哮喘的发展轨迹中得出:未来的重症哮喘决策树应重新审视当前的知识和差距。已进行了重点文献检索:专家意见:目前,哮喘严重程度的定义是先验性的,因此排除了早期干预的作用,早期干预的目的是防止病情恶化(接触全身性皮质类固醇)和肺功能下降等结果。哮喘 "高危 "可能是最终的范例,但需要进行纵向研究,考虑现代干预措施。真正的病情加重、严重的气道高反应性、过多的 T2 相关生物标志物、有害环境和患者行为、OCS 和大剂量吸入皮质类固醇(ICS)的危害以及含 ICS 吸入器的低依从性与有效比,都是未来风险的预测因素。应使用成像、遗传和表观遗传特征等新工具。逻辑和数字人工智能可用于生成一致的风险评分。对治疗反应进行务实的定义将有助于开发一种经过验证的适用算法。生物制剂最有可能将风险降至最低,但成本仍是一个问题。我们提出了一种简化的六步决策算法,其最终目标是实现哮喘缓解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Imagining the severe asthma decision trees of the future.

Introduction: There are no validated decision-making algorithms concerning severe asthma (SA) management. Future risks are crucial factors and can be derived from SA trajectories.

Areas covered: The future severe asthma-decision trees should revisit current knowledge and gaps. A focused literature search has been conducted.

Expert opinion: Asthma severity is currently defined a priori, thereby precluding a role for early interventions aiming to prevent outcomes such as exacerbations (systemic corticosteroids exposure) and lung function decline. Asthma 'at-risk' might represent the ultimate paradigm but merits longitudinal studies considering modern interventions. Real exacerbations, severe airway hyperresponsiveness, excessive T2-related biomarkers, noxious environments and patient behaviors, harms of OCS and high-doses inhaled corticosteroids (ICS), and low adherence-to-effectiveness ratios of ICS-containing inhalers are predictors of future risks. New tools such as imaging, genetic, and epigenetic signatures should be used. Logical and numerical artificial intelligence may be used to generate a consistent risk score. A pragmatic definition of response to treatments will allow development of a validated and applicable algorithm. Biologics have the best potential to minimize the risks, but cost remains an issue. We propose a simplified six-step algorithm for decision-making that is ultimately aiming to achieve asthma remission.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信